Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is seeking applications for the Catalyze Program, which aims to provide support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates. This specific initiative will provide early-stage translational support for activities required to identify and characterize potential therapeutic candidates and combination products to treat heart, lung, blood, and sleep (HLBS) diseases and disorders. The program will support the development of small molecules, biologics, and combination products. Key aspects of the program include: • Preliminary product/lead series identification • Combination product prototype development • Support for the transition of basic science discoveries into viable diagnostic and therapeutic candidates • Development of translational researchers fluent in product development and entrepreneurship The program is part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.